康哲药业:2024年全年正常经营利润下降近10亿,主要因集采影响毛利约86亿

市场资讯
20 Mar

  来源:Gangtise投研

  康哲药业 (00867.HK)  2024年度业绩发布会:康哲药业2024年业绩发布会总结:公司2024年业绩符合预期,营业额受集采影响上半年下降,下半年同比正增长约10%,全年正常经营利润下降近10亿,主要因集采影响毛利约86亿,研发投入增加超1亿,新产品推广开支多出1亿多。集采产品收入约26.9亿,维持2022年高峰时50%左右水平,独家和创新产品占比达52.8%。研发开支8.888亿,占营业额20%,其中费用化部分约3.3亿,占比3.8%。公司未来将立足亚洲,持续创新,推动国际化发展,2025年收入增长预计低于双位数,利润金额有望与收入规模持平,创新产品2025年销售额有望翻倍,利润率将逐渐提升。

海量资讯、精准解读,尽在新浪财经APP

责任编辑:王若云

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10